Korean Circ J.  2012 Aug;42(8):513-518. 10.4070/kcj.2012.42.8.513.

Epidemiology and Clinical Management of Pulmonary Hypertension in Children

• Jin H
• Yang J
• Zhang Q
• Du J

• KMID: 2224999
• DOI: http://doi.org/10.4070/kcj.2012.42.8.513

Abstract

Pulmonary hypertension (PH) is a clinical hemodynamic syndrome characterized by increased pulmonary artery pressure and pulmonary vascular resistance. It can cause right ventricular failure, and even death. Pediatric PH is not very common, but is a greatly hazardous disease that leads to a high mortality rate. Therefore, many registry organizations have been established in the world to strengthen the study of diagnosis and treatment of the disease, and improve the understanding of pediatric PH. This article reviewed recently published researches, as well as presented a comprehensive understanding of PH, including definition, classification, epidemiology, prognosis and treatment.

Keyword

Hypertension, pulmonary; Incidence; Disease management; Child

MeSH Terms

Child
Disease Management
Hemodynamics
Humans
Hydrogen-Ion Concentration
Hypertension, Pulmonary
Incidence
Prognosis
Pulmonary Artery
Vascular Resistance

Reference

1. Fasnacht MS, Tolsa JF, Beghetti M. Swiss Society for Pulmonary Arterial Hypertension. The Swiss registry for pulmonary arterial hypertension: the paediatric experience. Swiss Med Wkly. 2007. 137:510–513.

2. Haworth SG, Hislop AA. Treatment and survival in children with pulmonary arterial hypertension: the UK Pulmonary Hypertension Service for Children 2001-2006. Heart. 2009. 95:312–317.

3. Fraisse A, Jais X, Schleich JM, et al. Characteristics and prospective 2-year follow-up of children with pulmonary arterial hypertension in France. Arch Cardiovasc Dis. 2010. 103:66–74.

4. van Loon RL, Roofthooft MT, Hillege HL, et al. Pediatric pulmonary hypertension in the Netherlands: epidemiology and characterization during the period 1991 to 2005. Circulation. 2011. 124:1755–1764.

5. Berger RM, Beghetti M, Humpl T, et al. Clinical features of paediatric pulmonary hypertension: a registry study. Lancet. 2012. 379:537–546.

6. Barst RJ, McGoon MD, Elliott CG, Foreman AJ, Miller DP, Ivy DD. Survival in childhood pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management. Circulation. 2012. 125:113–122.

7. Zhou AQ, Zhang QY, DU JB. [Research on pulmonary hypertension in children: present and future]. Zhonghua Er Ke Za Zhi. 2011. 49:881–885.

8. Badesch DB, Champion HC, Sanchez MA, et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 2009. 54:1 Suppl. S55–S66.

9. Barst RJ, Ertel SI, Beghetti M, Ivy DD. Pulmonary arterial hypertension: a comparison between children and adults. Eur Respir J. 2011. 37:665–677.

10. Ivy D. Advances in pediatric pulmonary arterial hypertension. Curr Opin Cardiol. 2012. 27:70–81.

11. Ivy DD, Rosenzweig EB, Lemarié JC, Brand M, Rosenberg D, Barst RJ. Long-term outcomes in children with pulmonary arterial hypertension treated with bosentan in real-world clinical settings. Am J Cardiol. 2010. 106:1332–1338.

12. Fu LJ, Zhou AQ, Guo Y, Zhao PJ, Huang MR, Li F. [Adenosine for pulmonary vasodilator testing in children with idiopathic pulmonary arterial hypertension]. Zhonghua Er Ke Za Zhi. 2011. 49:886–889.

13. Zhang QY, Du JB. Progress on treatment or pulmonary hypertension in children. J Clin Pediatr. 2010. 28:607–610.

14. Tissot C, Ivy DD, Beghetti M. Medical therapy for pediatric pulmonary arterial hypertension. J Pediatr. 2010. 157:528–532.

15. Yung D, Widlitz AC, Rosenzweig EB, Kerstein D, Maislin G, Barst RJ. Outcomes in children with idiopathic pulmonary arterial hypertension. Circulation. 2004. 110:660–665.

16. Simonneau G, Barst RJ, Gaile N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2002. 165:800–804.

17. Rosenzweig EB, Krishnan U, Takatsuki S, Kerstein J, Calderbank M, Ivy DD. Inhaled treprostinil in pediatric pulmonary arterial hypertension. Am J Respir Crit Care Med. 2011. 183:A6143.

18. Ivy DD, Doran AK, Smith KJ, et al. Short- and long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension. J Am Coll Cardiol. 2008. 51:161–169.

19. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet. 2001. 358:1119–1123.

20. Simpson CM, Penny DJ, Cochrane AD, et al. Preliminary experience with bosentan as initial therapy in childhood idiopathic pulmonary arterial hypertension. J Heart Lung Transplant. 2006. 25:469–473.

21. Hislop AA, Moledina S, Foster H, Schulze-Neick I, Haworth SG. Long-term efficacy of bosentan in treatment of pulmonary arterial hypertension in children. Eur Respir J. 2011. 38:70–77.

22. Xu ZM, Zhu LM, Cai XM, Ji G, Liu JF, Su ZK. [Outcome of oral bosentan in children with congenital heart disease associated pulmonary arterial hypertension]. Zhonghua Yi Xue Za Zhi. 2009. 89:2106–2109.

23. van Loon RL, Hoendermis ES, Duffels MG, et al. Long-term effect of bosentan in adults versus children with pulmonary arterial hypertension associated with systemic-to-pulmonary shunt: does the beneficial effect persist? Am Heart J. 2007. 154:776–782.

24. Beghetti M, Hoeper MM, Kiely DG, et al. Safety experience with bosentan in 146 children 2-11 years old with pulmonary arterial hypertension: results from the European Postmarketing Surveillance program. Pediatr Res. 2008. 64:200–204.

25. Mourani PM, Sontag MK, Ivy DD, Abman SH. Effects of long-term sildenafil treatment for pulmonary hypertension in infants with chronic lung disease. J Pediatr. 2009. 154:379–384. 384.e1–384.e2.

26. Barst RJ, Ivy DD, Gaitan G, et al. A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension. Circulation. 2012. 125:324–334.

27. Fox BD, Shimony A, Langleben D. Meta-analysis of monotherapy versus combination therapy for pulmonary arterial hypertension. Am J Cardiol. 2011. 108:1177–1182.